Table 2 Clinical findings at transplant of patients undergoing allogeneic unrelated transplant

From: Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients

Patients, N

121

 Median age, years (range)

49 (17–65)

 Sex M/F (%)

69/52 (57/43)

Diagnosis

 ALL

2

 AML

25

 CML

3

 MDS

5

 MMF

6

 NHL

28

 B-CLL

9

 HD

41

 MF/SS

2

Conditioning regimens (%)

 TBI+Alem+Flud+Melph

50 (41)

 Thiotepa+Cyclophamide+ATG

71 (59)

Source of stem cell (%)

 BM

54 (45)

 PB

67 (55)

Disease status at transplant (%)

 Standard phase

41 (34)

 High-risk phase

80 (66)

Years of follow up, median (range)

2.43 (0.35–8.36)

  1. Abbreviations: Alem, alemtuzumab; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; ATG, anti-thymocyte globulin; B-CLL, B-cell chronic lymphocytic leukemia; BM, bone marrow; CML, chronic myeloid leukemia; F, female; Flud, fludarabine; HD, Hodgkin's disease; M, male; MDS, myelodysplastic Syndrome; Melph, melphalan; MF, mycosis fungoides; MMF, myelofibrosis; NHL, non-Hodgkin's lymphoma; PB, peripheral blood; SS, Sezary’s syndrome; TBI, total body irradiation.
Back to article page